{"id":"W3202278757","doi":"10.1016/j.annonc.2021.08.550","title":"267P Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) + entinostat (entino) in MORPHEUS-HR+ breast cancer (M-HR+BC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Oncology; Breast cancer; Internal medicine; Cancer; Cancer research; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001041605,0.001826817,0.001976911,0.0003336389,0.000368662,0.00131084,0.0007959889,0.001383321,0.01024536],"category_scores_gemma":[0.0007779432,0.0006780231,0.001911263,0.0003314514,0.0008428772,0.0008870528,0.0003344874,0.003832105,0.0021753],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001028468,"about_ca_system_score_gemma":0.001530702,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001466139,"about_ca_topic_score_gemma":0.004108036,"domain_scores_codex":[0.999728,0.0001098891,0.00001061234,0.00005347352,0.00002298085,0.0000749496],"domain_scores_gemma":[0.9996425,0.0000576679,0.00006415337,0.00003229605,0.00002800302,0.0001753902],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9376863,0.01155954,0.0006094841,0.0007178527,0.0009711031,0.0000494653,0.00005445003,0.000693893,0.006432569,0.0002909808,0.004114045,0.03682037],"study_design_scores_gemma":[0.9209731,0.07412028,0.001247489,0.00003803708,0.0003937277,0.00005625914,0.00002670723,0.0005341451,0.0005665128,0.0002407838,0.001787802,0.00001520069],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.96645,0.007183169,0.002097084,0.002087728,0.001068211,0.007453666,0.00547429,0.0004865437,0.007699322],"genre_scores_gemma":[0.9556765,0.007007555,0.004110297,0.003302024,0.00057293,0.008094458,0.006454576,0.0001249303,0.01465674],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01024536,"threshold_uncertainty_score":0.0342741,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.198666828918969,"score_gpt":0.4921568923871596,"score_spread":0.2934900634681906,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}